PolyI:polyC12U adjuvant-combined intranasal vaccine protects mice against highly pathogenic H5N1 influenza virus variants

The highly pathogenic avian H5N1 influenza virus has the potential to incite a global pandemic. Therefore, there is an urgent need to develop effective vaccines against these viruses. Because it is difficult to predict which strain of influenza will cause a pandemic, it is advantageous to develop va...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2009-10, Vol.27 (45), p.6276-6279
Main Authors: Ichinohe, Takeshi, Ainai, Akira, Tashiro, Masato, Sata, Tetsutaro, Hasegawa, Hideki
Format: Article
Language:English
Subjects:
Adjuvant
Adjuvants, Immunologic
Administration, Intranasal
Animals
Antibodies, Viral - blood
Antibody Formation
Avian flu
Clinical trials
Cross Protection
H5N1
Heterosubtypic immunity
Immune system
Immunity, Mucosal
Immunoglobulin A - immunology
Immunoglobulin G - blood
Infections
Influenza A Virus, H5N1 Subtype - immunology
Influenza Vaccines - immunology
Influenza virus
Intranasal vaccine
Mice
Mice, Inbred BALB C
Orthomyxoviridae Infections - immunology
Orthomyxoviridae Infections - prevention & control
Pandemics
Poly I-C - immunology
Poly U - immunology
Vaccines
Viruses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The highly pathogenic avian H5N1 influenza virus has the potential to incite a global pandemic. Therefore, there is an urgent need to develop effective vaccines against these viruses. Because it is difficult to predict which strain of influenza will cause a pandemic, it is advantageous to develop vaccines that will confer cross-protective immunity against variants of the influenza virus. Recently, we reported that the Toll-like receptor 3 agonist, polyI:polyC12U (Ampligen®), has been proven to be safe in a Phase III human trial, and is an effective mucosal adjuvant for intranasal H5N1 influenza vaccination. Intranasal administration of an Ampligen® adjuvanted pre-pandemic H5N1 vaccine (NIBRG14), which was derived from the A/Vietnam/1194/2004 strain, resulted in the secretion of vaccine-specific IgA and IgG in nasal mucosa and serum, respectively, and protected mice against homologous A/Vietnam/1194/2004 and heterologous A/Hong Kong/483/97 and A/Indonesia/6/2005 viral challenge.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2009.04.074